FAP+CAFs also belong to the pro-tumor CAFs subgroup, which can secrete CXCL12 to inhibit the accumulation of cytotoxic CD8+T cells in tumors, while the use of CXCL12 receptor chemokine receptor 4 inhibitor AMD3100 not only causes rapid accumulation of CD8+T cells among cancer cells, but also enhances the efficacy of anti-PD-L1 therapy [125]. Here, CXCL12 is linked to cancer.